CompletedPhase 1

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

United States27 participantsStarted 1999-01

Plain-language summary

Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for 7 days.

Who can participate

Age range18 Years – 65 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of idiopathic hypogonadotropic hypogonadism (IHH) or Kallmann syndrome (KS)Adult male 18-65 years of age * Serum testosterone \<100 ng/dL Exclusion Criteria: * No specific exclusion criteria

What they're measuring

testosterone

Timeframe: daily for 7 days

Timeframe: frequent sampling for 2 hours

FSH

Timeframe: frequent sampling for 2 hours

Inhibin B

Timeframe: daily for 7 days

free alpha subunit

Timeframe: daily for 7 days

Trial details

NCT IDNCT00493961

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-11-17

View on ClinicalTrials.gov More Kallmann Syndrome trials